Lokale und systemische Immunsuppression bei Pankreaskarzinompatienten
暂无分享，去创建一个
[1] H. Juhl,et al. Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: a new prognostic factor. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] H. Kalthoff,et al. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. , 1998, Cancer research.
[3] T. Eberlein,et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Matsuda,et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. , 1993, Cancer research.
[5] T. Eberlein,et al. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. , 1999, Surgery.
[6] W. Schmiegel,et al. TGFbeta-induced growth inhibition involves cell cycle inhibitor p21 and pRb independent from p15 expression. , 1999, International journal of oncology.
[7] A. Zlotnik,et al. Interleukin-10 and cancer. , 1993, Cancer investigation.